Clinical-to-Pathological Nodal Discordance and Postoperative Outcomes by EGFR Mutation Subtype in Resected Clinically Node-Positive Non-Small-Cell Lung Cancer
Cancers · 19.11.2026 · 18 (22) · 3704
DOI: 10.3390/cancers18223704 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancers, online erschienen am 19.11.2026. Verfasst von Takehiko Manabe und 14 weiteren Autor:innen. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background/Objectives: Clinical nodal classification may differ from postoperative pathological findings in lung cancer. We evaluated nodal discordance and mutation-specific outcomes in surgically treated, clinically node-positive epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancer.
Methods
This retrospective study included patients with clinical N1–2, stage II–III disease treated at four Japanese institutions from 2012 to 2020. EGFR exon 19 deletion (Del19) and exon 21 L858R point mutation (L858R) were compared in exploratory postoperative and post-recurrence survival analyses.
Results
Among 66 patients, 33 had Del19, 28 had L858R, and 5 had uncommon mutations; 52 underwent upfront surgery and 14 received preoperative treatment. Among 42 patients with clinical N1 disease, 18 (42.9%) had postoperative pathological N2 disease. The adjusted hazard ratio for postoperative overall survival with L858R versus Del19 was 1.99 (95% confidence interval, 0.97–4.09); the corresponding progression-free survival hazard ratio was 0.99 (0.54–1.81). In the pooled pathological common-mutation cohort, post-recurrence overall survival was evaluated in 33 patients with 25 deaths (univariable hazard ratio, 1.41; 95% confidence interval, 0.64–3.11; log-rank p = 0.388). Post-recurrence progression-free survival was evaluated in 26 patients and favored Del19 in an unadjusted comparison (log-rank p = 0.023).
Conclusions
Nodal discordance was frequent in this selected surgical population. The imprecise survival estimates establish neither equivalent prognosis nor an independent adverse effect of L858R. Post-recurrence findings require external validation with treatment-adjusted analyses.
Zitieren
APA
Manabe, T., Takenaka, M., Okawara, M., Tanaka, K., Fujita, Y., Hashimoto, T., Matsumiya, H., Mizuno, T., Miyata, R., Nonaka, Y., Hamaji, M., Ueda, K., Chen-Yoshikawa, T. F., Tanaka, F., & Uramoto, H. (2026). Clinical-to-Pathological Nodal Discordance and Postoperative Outcomes by EGFR Mutation Subtype in Resected Clinically Node-Positive Non-Small-Cell Lung Cancer. Cancers, 18(22), 3704. https://doi.org/10.3390/cancers18223704
Vancouver
Manabe T, Takenaka M, Okawara M, Tanaka K, Fujita Y, Hashimoto T, et al. Clinical-to-Pathological Nodal Discordance and Postoperative Outcomes by EGFR Mutation Subtype in Resected Clinically Node-Positive Non-Small-Cell Lung Cancer. Cancers. 2026;18(22):3704. doi:10.3390/cancers18223704
BibTeX
@article{Manabe2026,
author = {Manabe, Takehiko and Takenaka, Masaru and Okawara, Makoto and Tanaka, Kanji and Fujita, Yasuhiro and Hashimoto, Teppei and Matsumiya, Hiroki and Mizuno, Tetsuya and Miyata, Ryo and Nonaka, Yuto and Hamaji, Masatsugu and Ueda, Kazuhiro and Chen-Yoshikawa, Toyofumi Fengshi and Tanaka, Fumihiro and Uramoto, Hidetaka},
title = {Clinical-to-Pathological Nodal Discordance and Postoperative Outcomes by EGFR Mutation Subtype in Resected Clinically Node-Positive Non-Small-Cell Lung Cancer},
journal = {Cancers},
year = {2026},
volume = {18},
number = {22},
pages = {3704},
doi = {10.3390/cancers18223704}
}
EUVIMED